Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07526493) titled 'Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases' on April 3.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Tongji Hospital
Condition:
Multiple Sclerosis (MS)
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Autoimmune Encephalitis (AE)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Myasthenia Gravis (MG)
Anti-Myelin Oligodendrocyte Glycoprotein Immunoglobulin G Antibody...